5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Innova Captab Ltd.

•
innovacaptab.comBSE: 544067NSE: INNOVACAP
Market Cap₹ 6,721 Cr.
Current Price
High / Low₹ 1,200 / 622
Stock P/E69.5
Book Value₹ 161
Price to Book4.44
Dividend Yield0.17 %
ROCE10.8 %
ROE9.8 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Drugs & Pharmaceutical Products: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 57.9% YoY, showing strong momentum
  • Company has delivered good sales growth of 25.9% CAGR over last 5 years
  • Company comfortably covers its interest (8.3x coverage)
  • Company maintains a comfortable, low leverage position

CONS

  • Equity base is being diluted - shares outstanding up 19.2%
  • Expensive relative to growth - PEG of 5.2
  • Though reporting repeated profits, the company pays out little dividend (13.7%)
  • Rich enterprise valuation - EV/EBITDA of 25.8x

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.0037.67455633.710.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9100.0082.59241576.410.33902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4850.0084.58184478.410.78566.003.284921.0057.3219.2733.81
4.CIPLA1385.0033.19111888.390.94785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1121.0024.78111820.180.09990.20-34.908017.0023.9721.3924.54
6.LAURUSLABS1840.0090.9399417.450.11362.07123.942026.3129.1018.2031.50
7.LUPIN2111.0017.4696528.820.851416.9816.018276.8934.2828.8629.59
8.DRREDDY1154.0029.8996322.060.69435.60-69.108099.80-5.2113.7510.63
9.MANKIND2328.5547.0996179.610.04574.0929.124030.5912.8913.2426.30
10.AUROPHARMA1653.3025.6295127.230.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2427.0038.1068495.930.10482.83927.884018.4831.3520.3520.03
12.INNOVACAP1174.4543.006720.780.1744.1342.27470.8533.9415.0415.53
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
219212236198227240249243287290364358400
191185206175198207216214252261317333360
Operating Profit28263123283332283529472540
OPM %12.70%12.41%12.91%11.81%12.54%13.81%13.08%11.62%12.13%10.12%12.92%7.05%10.07%
1226543445333
Interest4540000235344
Depreciation33333338999910
Profit before Tax21202626303433232719372843
Tax %28.66%29.00%26.89%25.16%25.41%25.38%25.54%25.07%25.65%25.64%25.26%19.81%25.50%
Net Profit15141920222624172014282232
3.193.023.263.453.904.484.262.993.552.504.883.915.60

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3573734117858598659581,2991,412
3173223566877607578361,1521,270
Operating Profit4051549999108122147142
OPM %11.12%13.64%13.27%12.54%11.47%12.48%12.77%11.30%10.05%
0113911171813
Interest5545181421517
Depreciation1110671111173738
Profit before Tax243846897894120112128
Tax %20.17%25.70%25.56%25.34%26.50%27.25%25.37%25.16%24.20%
Net Profit192834665868898497
EPS159.85232.39287.5013.7911.9911.9115.6314.63—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%13.68%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
26%
3 Years:
15%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
19%
3 Years:
13%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
28%

RETURN ON EQUITY

10 Years:
—
5 Years:
19%
3 Years:
12%
Last Year:
10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jan 30

₹ 0.20

Interim Dividend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1212121248575757
7098133199220666756829
665446177245233302293
Trade Payables6072112140148154176288
2018672958699397
Total Liabilities2282543705567191,1801,3841,564
787379161161164637648
Capital Work in Progress0070223392115
00060606060101
3365911059794140204
00000217249330
Cash & Bank151221586682
115110180228364219209263
Total Assets2282543705567191,1801,3841,564

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
23405579581122034
Cash from Investing-9-6-20-188-88-472-100-14
Cash from Financing-10-23-191255136884-34
-013-5384-14

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
PER SHARE
EPS (₹)159.85232.38287.50551.4811.9911.9115.6314.63
Book Value (₹)683.71919.621206.841756.8955.90126.47142.06154.94
Dividend per Share (₹)0.000.000.000.000.000.000.002.00
Cash EPS (₹)6.227.918.3515.3314.2113.9018.6121.15
PROFITABILITY
Operating Margin %11.24%13.96%13.57%12.90%12.48%12.47%12.75%11.23%
Net Margin %5.38%7.46%8.38%8.42%6.69%7.87%9.33%6.41%
ROE %23.38%28.99%27.04%37.22%24.02%13.74%11.64%9.85%
ROCE %19.19%26.58%28.42%32.59%21.70%14.62%11.60%10.84%
8.43%11.58%11.06%14.29%9.02%7.18%6.98%5.68%
EFFICIENCY
Debtor Days97891007386948981
Inventory Days3448704643404548
Payable Days7610712389100109111117
5529473029262212
FINANCIAL HEALTH
Debt to Equity (x)0.87x0.48x0.31x0.84x0.88x0.33x0.40x0.36x
Interest Coverage (x)5.45x9.11x12.80x17.63x5.28x7.89x56.30x8.25x
1.44x1.39x1.26x1.20x1.46x1.94x1.77x1.78x
GROWTH
Revenue Growth %0.00%4.63%10.00%91.27%9.32%0.73%10.77%35.57%
Operating Profit Growth %0.00%30.24%6.94%81.47%5.82%10.65%17.18%18.36%
Net Profit Growth %0.00%45.37%23.72%91.82%-13.03%18.43%31.26%-6.46%
0.00%0.00%0.00%0.00%0.00%-0.66%31.26%-6.46%
VALUATION
P/E (x)0.00x0.00x0.00x0.00x0.00x37.62x56.12x47.00x
P/B (x)0.00x0.00x0.00x0.00x0.00x3.54x6.18x4.44x
Dividend Yield %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.29%
0.00x0.00x0.00x0.00x0.00x22.91x37.97x25.83x

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.9050.9050.9050.9050.9050.9050.9050.90
1.010.740.350.230.070.100.230.34
20.6119.9619.7719.6720.1720.2420.1419.92
Government0.000.000.000.000.000.000.000.00
27.4828.4128.9929.2028.8528.7628.7328.84

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-05
Copy of Newspaper Publication

2026-09-05 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-05
General Updates

2026-09-05 - Innova Captab Limited has informed the Exchange about General Updates

2026-09-04
Shareholders meeting

2026-09-04 - Innova Captab Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-03
Outcome of Board Meeting

2026-09-03 - Innova Captab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.

2026-08-23
Copy of Newspaper Publication

2026-08-23 - Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-22
General Updates

2026-08-22 - Pursuant to regulation 30 (read with part A of schedule III) and other applicable provisions ofSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )and with reference to the our letter dated 24th June, 2026 regarding postponement of22nd Annual General Meeting ( AGM ) of the Company and in continuation of intimation ofoutcome of the Board meeting of the Directors commenced on Friday, 21st August, 2026 at23:16 hours (IST) and concluded on Saturday, 22nd August, 2026 at 00:25 hours (IST), we wish toinform you that the Board of Directors has also approved the notice for calling 22nd AnnualGeneral Meeting ( AGM ) of the Company for the financial year 31st March, 2026. The 22nd AGMNotice along with the annual report will be submitted to the stock exchange(s) in due course oftime.

2026-08-22
Capacity addition

2026-08-22 - Innova Captab Limited has informed the Exchange about Capacity addition

2026-08-22
Outcome of Board Meeting

2026-08-22 - Innova Captab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for INNOVACAP

Loading news…

🤖

AI Stock Analyst

Innova Captab Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login